The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...
Gilead stock toppled Thursday after CVS HealthCVS said it won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now. The decision is based on clinical, financial and ...
(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback